Document is current
Any future updates will be listed below
-
Authors
Musokhranova, Uliana
Grau, Cristina
Vergara, Cristina
Rodríguez-Pascau, Laura
Xiol, Clara
Castells, Alba A.
Alcántara, Soledad
Rodríguez-Pombo, Pilar
Pizcueta, Pilar
Martinell, Marc
García-Cazorla, Angels
Oyarzábal, Alfonso http://orcid.org/0000-0001-9689-6072
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (RTC-2017-5867-1, PID2020-115748RB-I00)
Departament de Salut, Generalitat de Catalunya (PFP00201-PERIS)
- License Information
-
More Information
Article History
Received: 13 July 2023
Accepted: 12 October 2023
First Online: 26 October 2023
Declarations
:
: Fibroblast samples were collected with legal tutors informed consent, and ethical approval for its collection, use and storage was granted by the Institutional Ethics Committee of the Hospital Sant Joan de Déu. Controls were unrelated surgery surpluses from healthy donors. The mouse colony was maintained in the Animal Facilities of the University of Barcelona. All animal procedures were carried out according to European Union guidelines (Directive 2010/63/EU) and were approved by the University of Barcelona Committee on Animal Use and Care.
: Not applicable.
: Pilar Pizcueta, Cristina Vergara, Laura Rodríguez-Pascau and Marc Martinell are staff from the pharmaceutic company Minoryx Therapeutics. Marc Martinell and Pilar Pizcueta report a patent application (10198126) issued on January 15th 2019 for the use of leriglitazone described in this paper. The patent will be owned by those authors. Marc Martinell is the cofounder of Minoryx Threapeutics, focused on the development of therapies for rare neurodegenerative diseases. The rest of the authors declare no competing interests.
